2027 Summer Intern Purification Downstream Process Development
Regeneron Pharmaceuticals
Summary
Regeneron is currently seeking multiple 2027 Interns in Purification Downstream Process Development teams.
Job description
When & where
Location: Tarrytown, NY. Timeframe: full-time and onsite from May/June-August.
What you'll do
- Work alongside scientists and engineers developing downstream purification processes for protein-based therapeutics at bench and pilot scale.
- Projects may include affinity chromatography, UF/DF, VRF, and Raman spectroscopy applications.
- Design and execute laboratory experiments, compile development data, conduct analyses, and support process optimization.
- Support continuous-improvement initiatives and development of streamlined data workflows.
Relevant majors: Chemical Engineering, Biomedical Engineering or related.
Let's find out if we're a fit
- Demonstrated leadership in areas such as campus activities, clubs, sports, current or previous work, or within the community preferred.
- Must be enrolled in, or accepted to, an academic program pursuing an Undergraduate or Graduate degree (and be returning to school the semester following the position or graduating after the position).
- Cumulative GPA of 3.0 or higher preferred.
Requirements
- Must be enrolled in, or accepted to, an academic program pursuing an Undergraduate or Graduate degree (and be returning to school the semester following the position or graduating after the position)
- Relevant majors: Chemical Engineering, Biomedical Engineering or related
- Cumulative GPA of 3.0 or higher preferred
- Demonstrated leadership in campus activities, clubs, sports, work, or community preferred
Benefits
- Annual Bonuses
- Incentive Plans
- Equity Awards
- Pension/Retirement Benefits
- 401(k) Matching
- Health & Wellness Programs
- Fitness Centers
- Medical, Dental & Vision
- Paid Time Off
- Family Support Benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.